On May 28, 2024 Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, reported that Cantex’s azeliragon, a well-tolerated once-a-day pill that inhibits "RAGE" (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO (Free ASCO Whitepaper) Annual Meeting to be held in Chicago (Press release, Cantex, MAY 28, 2024, View Source [SID1234643754]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The 2024 ASCO (Free ASCO Whitepaper) Annual Meeting represents an important opportunity to meet with the leading oncology researchers from around the world and showcase the progress of azeliragon clinical investigations at leading cancer centers in several difficult-to-treat cancers," said Stephen G. Marcus, M.D., Cantex’s Chief Executive Officer.
2024 ASCO (Free ASCO Whitepaper) Annual Meeting Abstracts:
Title: A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer.
Abstract #: TPS4212
Title: Azeliragon, a RAGE inhibitor, in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II CAN-201 NDG trial design.
Abstract #: TPS2096
Title: RAGE inhibition to decrease cancer therapy related cardiotoxicity in women with early breast cancer (RAGE).
Abstract #: TPS619
Title: A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION).
Abstract #: TPS2093
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer’s disease by vTv Therapeutics Inc. (NASDAQ: VTVT) from which Cantex licensed worldwide rights to azeliragon. Clinical safety data from these trials, involving more than 2000 individuals dosed for periods up to 18 months, indicate that azeliragon is very well tolerated.
Cantex has ongoing Phase II clinical trials in pancreatic cancer, glioblastoma, brain metastasis, breast cancer, and a Phase 3 trial in hospitalized patients with pneumonia to prevent acute kidney injury. These trials are based on azeliragon’s robust preclinical data as well as its extensive clinical safety information from randomized placebo-controlled clinical trials.
Azeliragon has U.S. Food and Drug Administration (FDA) orphan drug designation for the treatment of pancreatic cancer and glioblastoma. FDA Orphan Drug Designation provides Cantex with seven years of azeliragon marketing exclusivity from the time of product launch for the orphan indication, and several other important benefits, including assistance in the drug development process, tax credits for clinical costs, and exemptions from certain FDA fees.